Castle Biosciences Inc CSTL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CSTL is a good fit for your portfolio.
News
-
DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck
-
Castle Biosciences Reports First Quarter 2024 Results
-
Castle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT Melanoma
-
Castle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024
-
Castle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational Collaborations
-
Castle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive Year
-
Presentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin Cancer
-
Castle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
Trading Information
- Previous Close Price
- $22.84
- Day Range
- $22.78–25.91
- 52-Week Range
- $9.26–26.70
- Bid/Ask
- $23.70 / $24.25
- Market Cap
- $671.19 Mil
- Volume/Avg
- 839,813 / 243,669
Key Statistics
- Price/Earnings (Normalized)
- 73.15
- Price/Sales
- 2.62
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Core
- Total Number of Employees
- 638
Comparables
Valuation
|
Metric
|
CSTL
|
GH
|
MYGN
|
|---|---|---|---|
Price/Earnings (Normalized) | 73.15 | — | — |
Price/Book Value | 1.67 | 14.47 | 2.23 |
Price/Sales | 2.62 | 3.75 | 2.14 |
Price/Cash Flow | 24.57 | — | — |
Price/Earnings
CSTL
GH
MYGN
Financial Strength
|
Metric
|
CSTL
|
GH
|
MYGN
|
|---|---|---|---|
Quick Ratio | 8.82 | 6.11 | 1.64 |
Current Ratio | 9.25 | 6.54 | 2.01 |
Interest Coverage | −1,996.48 | −198.43 | −90.28 |
Quick Ratio
CSTL
GH
MYGN
Profitability
|
Metric
|
CSTL
|
GH
|
MYGN
|
|---|---|---|---|
Return on Assets (Normalized) | 2.04% | −20.62% | −1.93% |
Return on Equity (Normalized) | 2.31% | −253.35% | −2.88% |
Return on Invested Capital (Normalized) | 0.02% | −25.20% | −2.33% |
Return on Assets
CSTL
GH
MYGN
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Yytdyvnjz | Pzch | $218.5 Bil | |
DHR
| Danaher Corp | Crcqchfyd | Brylztv | $184.0 Bil | |
A
| Agilent Technologies Inc | Plqgzxmch | Rjj | $40.9 Bil | |
IQV
| IQVIA Holdings Inc | Fdkjbvl | Qrbvjx | $40.7 Bil | |
IDXX
| IDEXX Laboratories Inc | Rbbxfxqk | Xqdjn | $39.7 Bil | |
MTD
| Mettler-Toledo International Inc | Pfzvcgdg | Thwdmnq | $26.8 Bil | |
ICLR
| Icon PLC | Vvzxgzr | Zxzms | $25.6 Bil | |
WAT
| Waters Corp | Nzfcjbwbr | Sygn | $19.1 Bil | |
ILMN
| Illumina Inc | Wxqlvgmx | Wfsxyl | $18.8 Bil | |
LH
| Laboratory Corp of America Holdings | Tmmzwmnq | Jmhzv | $17.0 Bil |